Farxiga Medicare Advantage Coverage: How to Get Dapagliflozin Covered in 2026

How Medicare Advantage Plans Classify Farxiga on Their Formularies

Farxiga sits on the formulary of most major Medicare Advantage prescription drug plans (MA-PDs), but the tier placement varies by insurer. Tier placement determines your copay or coinsurance, so identifying where your specific plan lists dapagliflozin is the first step toward estimating your annual cost.

Among the largest MA-PD carriers (UnitedHealthcare, Humana, Aetna, Cigna, and Blue Cross affiliates), Farxiga appears on tier 3 or tier 4 in most 2026 plan formularies. Tier 3 ("preferred brand") copays typically range from $35 to $47 per 30-day supply. Tier 4 ("non-preferred brand") plans may charge 25% to 33% coinsurance, which on a $620 list price translates to $155 to $205 before any catastrophic or cap protections apply. A 2023 analysis published in Diabetes Care found that SGLT2 inhibitors were placed on non-preferred tiers in 37% of Medicare Part D standalone plans, creating significant cost barriers for beneficiaries with type 2 diabetes and cardiovascular comorbidities 1.

You can verify your plan's tier by searching the Medicare Plan Finder at medicare.gov or calling the number on your member ID card. Formularies update quarterly, so a mid-year check is worth the five minutes it takes.

Some plans impose quantity limits of 30 tablets per 30 days (one tablet daily), which aligns with the FDA-approved dosing for all three indications. Requests exceeding this quantity require a coverage determination. The CMS formulary reference file, updated annually, shows that 89% of MA-PD plans listed at least one SGLT2 inhibitor in 2025, though empagliflozin (Jardiance) sometimes occupies the preferred slot over dapagliflozin depending on the plan's pharmacy benefit manager contract 2.

The $2,000 Out-of-Pocket Cap Changes Everything for 2025 and 2026

The Inflation Reduction Act (IRA) introduced a $2,000 annual cap on Part D out-of-pocket spending, effective January 1, 2025. This is the single largest change to Medicare drug costs in the program's history, and it directly benefits anyone filling a branded SGLT2 inhibitor.

Before this cap, Medicare beneficiaries in the coverage gap ("donut hole") paid 25% coinsurance on brand drugs until they reached the catastrophic threshold of roughly $8 to 000 in true out-of-pocket spending. A patient filling Farxiga at $620 per month would spend approximately $1 to 860 in coinsurance during the gap alone. Under the new structure, once your cumulative out-of-pocket drug costs hit $2 to 000 in a calendar year, you pay nothing for the remainder of that year 3.

For a beneficiary taking only Farxiga and no other costly medications, this cap is typically reached between months 4 and 7, depending on the plan's copay or coinsurance structure. A tier-3 copay of $47 per month means you would not hit the cap on Farxiga alone during the year. A tier-4 coinsurance of 25% ($155/month) means you cross the $2,000 threshold around month 13, but if you take other brand medications, you reach it sooner.

CMS also introduced the Medicare Prescription Payment Plan, which allows beneficiaries to spread their out-of-pocket costs across monthly installments rather than paying large sums at the pharmacy counter. Enrollment is available through your MA-PD plan or at 1-800-MEDICARE 4.

According to a Kaiser Family Foundation analysis, 1.4 million Medicare Part D enrollees spent more than $2,000 out-of-pocket on prescriptions in 2021, and SGLT2 inhibitors were among the top 20 drugs driving high out-of-pocket spending in that cohort 5.

Prior Authorization: What Medicare Advantage Plans Require

Prior authorization (PA) is the most common access barrier for Farxiga under Medicare Advantage. The plan requires your prescriber to submit clinical documentation proving that dapagliflozin is medically necessary before the pharmacy can fill it.

Typical PA criteria for Farxiga on MA-PD plans include: a confirmed diagnosis of type 2 diabetes, heart failure (NYHA class II-IV), or chronic kidney disease with eGFR 25-75 mL/min/1.73m²; documentation that the patient has tried or is currently taking metformin (for diabetes indications); and lab values confirming the relevant diagnosis. Some plans also require documentation of an A1C level above 7% if the indication is glycemic control.

PA approval periods range from 6 to 12 months. Denials can be appealed through the plan's internal process, and if upheld, through an independent review entity (IRE). CMS data from 2023 showed that 82% of prior authorization requests for Part D drugs were approved on initial submission, and the approval rate rose to 85% after one appeal 6.

The DAPA-HF trial (N=4,744) demonstrated a 26% reduction in the composite of cardiovascular death or worsening heart failure with dapagliflozin versus placebo 7. The DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death 8. Citing these trials in a PA letter strengthens the case for medical necessity, particularly when the indication is heart failure or CKD rather than diabetes.

Dr. Mikhail Kosiborod, a cardiologist at Saint Luke's Mid America Heart Institute and co-principal investigator of DAPA-HF, stated: "The benefit of SGLT2 inhibitors in heart failure is consistent regardless of diabetes status, and access barriers should not delay initiation in eligible patients" 7.

Step Therapy and Formulary Alternatives

Some Medicare Advantage plans require step therapy before approving Farxiga. This means you must try (and document inadequate response to or intolerance of) a less expensive medication first. For diabetes indications, the required first step is almost always metformin.

If your plan prefers Jardiance (empagliflozin) over Farxiga, your prescriber has two options. First, submit a formulary exception request arguing that dapagliflozin is medically necessary for your specific clinical situation. Valid reasons include prior adverse reaction to empagliflozin, a CKD indication where dapagliflozin has the specific FDA approval (Jardiance received its CKD indication in 2025, but DAPA-CKD was the first positive trial in this space), or concomitant medications that interact differently with one SGLT2 inhibitor versus another. Second, switch to the plan's preferred SGLT2 inhibitor if there is no clinical reason to prefer dapagliflozin specifically. Both drugs belong to the same pharmacologic class, and the 2024 ADA Standards of Care do not preferentially recommend one over the other for type 2 diabetes management 9.

The American College of Cardiology's 2022 Heart Failure Guideline gives a Class I recommendation for SGLT2 inhibitors (dapagliflozin or empagliflozin) in patients with HFrEF, regardless of diabetes status 10. For patients with HFpEF, the DELIVER trial (N=6,263) showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 18% versus placebo 11. This evidence supports exception requests when a plan tries to steer patients away from dapagliflozin.

Extra Help (Low-Income Subsidy) and State Pharmaceutical Assistance

Medicare Extra Help, also called the Low-Income Subsidy (LIS), dramatically reduces prescription costs for beneficiaries with limited income and resources. For 2026, beneficiaries who qualify for full Extra Help pay $0 for generic drugs and no more than $4.50 for brand-name drugs per fill. Partial subsidy beneficiaries pay a reduced copay that varies by plan but is capped well below standard tier-4 coinsurance.

Eligibility thresholds for 2026 are approximately $23,000 annual income for an individual and $31,000 for a married couple, with asset limits of $17,000 and $34,000 respectively (excluding home and vehicle). Applications go through the Social Security Administration at ssa.gov or your local Medicaid office 12.

State Pharmaceutical Assistance Programs (SPAPs) exist in roughly 20 states and can supplement Medicare Part D coverage. States like New York (EPIC), Pennsylvania (PACE/PACENET), and Connecticut (ConnPACE) provide additional premium or copay assistance for branded drugs. SPAP spending counts toward the Part D out-of-pocket threshold, which means these programs can push you past the $2,000 cap faster.

Dr. Stacie Dusetzina, a health policy researcher at Vanderbilt University Medical Center, noted in a 2024 JAMA Internal Medicine commentary: "Even with the IRA cap, beneficiaries who do not qualify for Extra Help and take multiple branded medications will still face meaningful cost barriers in the initial coverage phase" 13.

AstraZeneca's Patient Assistance Programs

AstraZeneca operates the AZ&Me Prescription Savings Program, which provides free Farxiga to uninsured or underinsured patients who meet income criteria. The program is available to U.S. residents with household income at or below 400% of the federal poverty level (approximately $62,400 for an individual in 2026) 14.

There is a critical limitation. Federal law prohibits manufacturer copay cards and coupons from being used by Medicare beneficiaries (including those enrolled in Medicare Advantage). The AstraZeneca Farxiga Savings Card, which can reduce copays to as low as $0 for commercially insured patients, cannot be applied to Medicare Part D or MA-PD prescriptions. This restriction stems from the Anti-Kickback Statute, which treats manufacturer subsidies to federal healthcare program beneficiaries as potential inducements.

The AZ&Me program for uninsured patients is separate from the copay card and is available to Medicare beneficiaries only if they have no Part D coverage at all. If you are enrolled in a Medicare Advantage plan with prescription drug coverage, you are generally ineligible for AZ&Me even if your out-of-pocket costs are high.

Patient Advocate Foundation (patientadvocate.org) and NeedyMeds (needymeds.org) maintain updated databases of copay assistance funds, some of which are disease-specific (heart failure, CKD, diabetes) and can help Medicare beneficiaries with cost sharing. These independent charitable funds are legally permitted to assist Medicare patients, unlike manufacturer coupons.

Generic Dapagliflozin: Timeline and What It Means for Cost

No generic dapagliflozin is available in the United States as of May 2026. AstraZeneca holds composition-of-matter patents and regulatory exclusivities that are expected to prevent generic entry until 2027 at the earliest. Several ANDA filers, including Teva and Zydus, have submitted abbreviated new drug applications, but FDA approval and launch timelines remain uncertain.

When a generic does reach the market, two things change. First, the list price drops by an estimated 70% to 85% based on historical patterns for branded cardiovascular drugs 15. Second, Medicare formularies reclassify the drug to tier 1 or tier 2, reducing copays to the $1 to $15 range. Prior authorization requirements also typically disappear for generics in well-established drug classes.

The IRA also gave Medicare the authority to negotiate prices directly with manufacturers for certain high-cost drugs. Farxiga was not among the first 10 drugs selected for negotiation in 2023, nor the second batch of 15 announced for 2025. Given the anticipated generic entry, it is unlikely to be selected for future negotiation rounds, as the program targets drugs without imminent generic competition.

In the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin reduced the rate of cardiovascular death or hospitalization for heart failure by 17% versus placebo in patients with type 2 diabetes and established atherosclerotic cardiovascular disease or multiple risk factors 16. This trial established the cardiovascular safety and efficacy profile that supports the broad formulary inclusion Farxiga currently enjoys.

Practical Steps to Lower Your Farxiga Costs Under Medicare Advantage

Reducing your out-of-pocket spending on Farxiga requires a specific sequence of actions, not vague advice to "shop around."

Check your formulary tier first. Log in to your MA-PD plan's member portal or call member services. If Farxiga is on tier 4, ask your prescriber to submit a tier exception request to move it to tier 3. Plans must grant exceptions when the prescriber documents that the preferred-tier alternative is clinically inappropriate.

Compare plans during Annual Enrollment (October 15 through December 7). Use Medicare Plan Finder to model your total annual drug costs across available MA-PD plans in your zip code. Enter all your medications, including Farxiga, and sort by estimated annual cost. Plans with lower Farxiga tiers may have higher premiums, so compare the total (premium plus out-of-pocket) rather than copay alone.

Apply for Extra Help if your income qualifies. Even partial LIS reduces your costs substantially. Use a 90-day mail-order pharmacy if your plan offers one. Many MA-PD plans charge 2.5 times the 30-day copay for a 90-day supply (instead of 3 times), which saves one copay every quarter.

If you are prescribed Farxiga for CKD or heart failure rather than diabetes, ensure the PA letter cites the correct indication-specific trial data. DAPA-CKD for kidney disease 8, DAPA-HF for HFrEF 7, and DELIVER for HFpEF 11 each provide indication-specific evidence that strengthens approval odds. A vague PA letter citing only "SGLT2 inhibitor benefit" is more likely to trigger a denial.

The $2,000 cap means your maximum annual exposure to Farxiga costs is bounded regardless of tier. For most beneficiaries, the combination of the IRA cap, careful plan selection, and (if eligible) Extra Help reduces the effective monthly cost of Farxiga to between $0 and $47 per fill for the entire year.